AUSTIN, TEXAS / ACCESS Newswire / July 8, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) (“Monogram” or the “Company”), an ...

Ben Sexson, Monogram CEO, stated, "This FDA 510(k) clearance is a defining moment for Monogram. It marks the culmination of years of relentless effort, innovation, and teamwork.

Monogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA System ACCESS Newswire. March 17, 2025 7:20 AM. Monogram May Market the Monogram mBôs™ TKA System, Subject to ...

Monogram has obtained FDA clearance for mPress implants and applied for 510(k) clearance for its robotic products. The Company is required to obtain FDA clearance before it can market its products.

The Application was submitted on July 19, 2024, and passed the initial FDA Administrative Review. On September 30, 2024, Monogram received an Additional Information Request ("AIR") from the FDA.

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT FDA Response to 510(k) Filing On October 6, 2024, Monogram (NASDAQ:MGRM) announced it had received an Additional Information ...

Monogram Orthopaedics Inc., a medical technology company focused on reconstructive joint procedures and surgical robotics, today announced the filing of an 8- K with the U.S. Securities and ...

Ben Sexson, Monogram Chief Executive Officer, commented, "This FDA 510(k) clearance is a defining moment for Monogram. It marks the culmination of years of relentless effort, innovation, and teamwork.

Monogram Technologies Submits 510(k) Application for mBôs TKA System Clearance ACCESSWIRE. Updated August 08, 2024 8:16 AM. Application was Submitted on July 19, 2024, Passed the FDA ...

FDA Decision is Expected Within 90 Days of Initial Submission; However, the Process May be Paused if Additional Information is Requested AUSTIN, TX / ACCESSWIRE / August 8, 2024 / Monogram ...